Substituted coumarins as potent 5-lipoxygenase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 9, 2006, Pages 2528-2531

  Grimm, Erich L ^a   Brideau, Christine ^a   Chauret, Nathalie ^a   Chan, Chi Chung ^a   Delorme, Daniel ^a   Ducharme, Yves ^a   Ethier, Diane ^a   Falgueyret, Jean Pierre ^a   Friesen, Richard W ^a   Guay, Jocelyne ^a   Hamel, Pierre ^a   Riendeau, Denis ^a   Soucy Breau, Chantal ^a   Tagari, Philip ^a   Girard, Yves ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

5 Lipoxygenase; Coumarin; Leukotrienene inhibitor; Structure activity relationship

Indexed keywords

2 CYANO 7 [3 FLUORO 5 (3 HYDROXY 6,8 DIOXABICYCLO[3.2.1]OCT 3 YL)PHENOXYMETHYL] 4 (3 FURYL)QUINOLINE; 3 [6 [7 CYANO 5 (3 FURYL) 2 NAPHTHOXYMETHYL] 2 PYRIDYL] 3 HYDROXY 6,8 DIOXABICYCLO[3.2.1]OCTANE; ARACHIDONATE 5 LIPOXYGENASE; COUMARIN DERIVATIVE; L 737010; LEUKOTRIENE; LIPOXYGENASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; IC 50; MOLECULAR MODEL; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; STRUCTURE ACTIVITY RELATION;

ARACHIDONATE 5-LIPOXYGENASE; COUMARINS; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33644979894     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.01.085     Document Type: Article

References (35)

1. H. Masamune, and L.S. Melvin Jr. R.C. Allen Annual Reports in Medicinal Chemistry Vol. 24 1989 Academic Press San Diego 71
2. B. Samuelson Science 220 1983 568
3. E. Israel, R. Dermarkarian, M. Rosenberg, R. Sperling, G. Taylor, P. Rubin, and J.M. Drazen N. Eng. J. Med. 323 1990 1740
4. E.H. Bel, W. Tanaka, R. Spector, B. Friedman, H. von de Veen, J.H. Dijkman, and P.J. Sterk Am. Rev. Respir. Dis. 141 1990 A31
5. T. Mano, R.W. Stevens, K. Ando, M. Kawai, K. Kawamura, K. Nakao, Y. Okumura, T. Okumura, M. Sakakibara, K. Miyamoto, and T. Tamura Chem. Pharm. Bull. 53 2005 965
6. T. Mano, R.W. Stevens, Y. Okumura, M. Kawai, T. Okumura, and M. Sakakibara Bioorg. Med. Chem. Lett. 15 2005 2611
7. T. Mano, R.W. Stevens, K. Nakao, Y. Okumura, K. Kawamura, A. Ando, and Y. Matsuoka Synthesis 2004 2625 and earlier papers in this series
8. G.V.M. Sharma, S. Punna, P. Radha Krishna, M.S. Chorghade, and S.V. Ley Tetrahedron: Asymmetry 16 2005 1125
9. T.A. Lewis, L. Bayless, J.B. Eckman, J.L. Ellis, G. Grewal, L. Libertine, J.M. Nicolas, R.T. Scannell, B.F. Wels, K. Wenberg, and D.M. Wypij Bioorg. Med. Chem. Lett. 14 2004 2265
10. C.D.W. Brooks, and J.B. Summers J. Med. Chem. 39 1996 2629
11. R.N. Young Eur. J. Med. Chem. 34 1999 671
12. A. Balkan, and B. Berk Curr. Med. Chem.-Anti-Inflamm. Anti-Allergy Agents 2 2003 9
13. F. Julémont, J.-M. Dogné, D. Laeckmann, B. Pirotte, and X. de Laval Expert Opin. Ther. Patents 13 2003 1
14. C.D. Funk Nat. Rev. 4 2005 664
15. O. Werz, and D. Steinhilber Expert Opin. Ther. Patents 15 2005 505
16. R. Yoshimura, M. Matsuyama, K. Kuratsukuri, K. Tsuchida, Y. Takemoto, and T. Nakatani Drugs Future 30 2005 351
17. P. Hamel, D. Riendeau, C. Brideau, C.-C. Chan, S. Desmarais, D. Delorme, D. Dubé, Y. Ducharme, D. Ethier, E. Grimm, J.-P. Falgueyret, J. Guay, T.R. Jones, E. Kwong, M. McAuliffe, C.S. McFarlane, H. Piechuta, M. Roumi, P. Tagari, R.N. Young, and Y. Girard J. Med. Chem. 40 1997 2866
18. D. Dubé, M. Blouin, C. Brideau, C.-C. Chan, S. Desmarais, D. Ethier, J.-P. Falgueyret, R.W. Friesen, M. Girard, Y. Girard, J. Guay, D. Riendeau, P. Tagari, and R.N. Young Bioorg. Med. Chem. Lett. 8 1998 1255
19. N. Chauret, D. Nicoll-Griffith, R. Friesen, C. Li, L. Trimble, D. Dubé, R. Fortin, Y. Girard, and J. Yergey Drug Metab. Dispos. 23 1995 1325
20. K.E. Zhang, J.A. Naue, B. Arison, and K.A. Vyas Chem. Res. Toxicol. 9 1996 547
21. Fortin, R.; Girard, Y.; Grimm, E.; Hutchinson, J.; Scheigetz, J. U.S. Patent 5,424,320, 1995.
22. J.-P. Falgueyret, D. Denis, D. Macdonald, J.H. Hutchinson, and D. Riendeau Biochemistry 34 1995 13603
23. C. Brideau, C. Chan, S. Charlson, D. Denis, J.F. Evans, A.W. Ford-Hutchinson, R. Fortin, J.W. Gillard, J. Guay, D. Guévremont, J.H. Hutchinson, T.R. Jones, S. Léger, J.A. Mancini, C.S. McFarlane, C. Pickett, H. Piechuta, P. Prasit, D. Riendeau, C.A. Rouzer, P. Tagari, P.J. Vickers, R.N. Young, and W.M. Abraham Can. J. Physiol. Pharmacol. 70 1992 799
24. T.G.C. Bird, P. Bruneau, G.C. Crawley, M.P. Edwards, S.J. Foster, J.-M. Girodeau, J.F. Kingston, and R.M. McMillan J. Med. Chem. 34 1991 2176
25. Compound 12 was prepared by treating 1 with 1M NaOH (2 equiv) in THF (65°C, 2 h). The solvent was evaporated, the residue was dissolved in de-ionized water, and the solution was lyophilized to give 12 as a light yellow powder.
26. 50 n.d.
27. D. Riendeau, J. Guay, A. Foster, S. Wolfe, and C.-C. Chan Gen. Pharmacol. 22 1991 371
28. P. Tagari, A. Becker, C. Brideau, R. Frenette, V. Sadl, E. Thomas, P. Vickers, and A. Ford-Hutchinson J. Pharmacol. Exp. Ther. 265 1993 416
29. Chauret, N. unpublished results.
30. A. Russel, and J.R. Frye Org. Synth. III 1955 281
31. J.P. Schaefer, and J. Higgins J. Org. Chem. 32 1967 1607
32. S. Clavier, Ø. Rist, S. Hansen, L.-O. Gerlach, T. Högberg, and J. Bergman Org. Biomol. Chem. 1 2003 4248
33. O. Nishimura, C. Kitatda, and M. Fujino Chem. Pharm. Bull. 26 1978 1576
34. For prodrug strategies based on intramolecular cyclization reactions see: D. Shan, M.G. Nicolaou, R.T. Borchardt, and B. Wang J. Pharm. Sci. 86 1997 765
35. A. Zheng, W. Wang, H. Zhang, and B. Wang Tetrahedron 55 1999 4237 and references cited therein